Involvement of Integrin-Activating Peptides Derived from Tenascin-C in Cancer Aggression and New Anticancer Strategy Using the Fibronectin-Derived Integrin-Inactivating Peptide

Systemic Chemotherapy for Metastatic Colitis-Associated Cancer has a Worse Outcome than for Sporadic Colorectal Cancer: a Matched Case Cohort Analysis

(2020) Rona Yaeger et al.   Clinical Colorectal Cancer

Integrin Signaling in Glioma Pathogenesis: From Biology to Therapy

(2020) Aleksandra Ellert-Miklaszewska et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Extracellular matrix-derived peptides in tissue remodeling and fibrosis

(2020) Lisandra E. de Castro Brás et al.   MATRIX BIOLOGY

Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C

(2020) Anna Mary Steitz et al.   Cell Death & Disease

The role of Tenascin-C and Twist1 in gastric cancer: cancer progression and prognosis

(2019) Wenbo Qi et al.   APMIS

Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease

(2019) J. Qi et al.   Acta Neuropathologica Communications

Peptide TNIIIA2 Derived from Tenascin-C Contributes to Malignant Progression in Colitis-Associated Colorectal Cancer via β1-Integrin Activation in Fibroblasts

(2019) Motomichi Fujita et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Autocrine Production of PDGF Stimulated by the Tenascin-C-Derived Peptide TNIIIA2 Induces Hyper-Proliferation in Glioblastoma Cells

(2019) Motomichi Fujita et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Aggressive Progression in Glioblastoma Cells through Potentiated Activation of Integrin α5β1 by the Tenascin-C-derived Peptide TNIIIA2

(2019) Motomichi Fujita et al.   MOLECULAR CANCER THERAPEUTICS

Are Integrins Still Practicable Targets for Anti-Cancer Therapy?

(2019) Alday-Parejo et al.   Cancers

High Co-expression of Large Tenascin C Splice Variants in Stromal Tissue and Annexin A2 in Cancer Cell Membranes is Associated with Poor Prognosis in Pancreatic Cancer

(2019) Kei Hagiwara et al.   ANNALS OF SURGICAL ONCOLOGY

Tumor microenvironment components: Allies of cancer progression

(2019) Pablo Igor Ribeiro Franco et al.   PATHOLOGY RESEARCH AND PRACTICE

A Matricryptic Conformation of the Integrin-Binding Domain of Fibronectin Regulates Platelet-Derived Growth Factor-Induced Intracellular Calcium Release

(2019) Christopher S. Farrar et al.   Cells

Dietary Fucoxanthin Induces Anoikis in Colorectal Adenocarcinoma by Suppressing Integrin Signaling in a Murine Colorectal Cancer Model

(2019) Masaru Terasaki et al.   Journal of Clinical Medicine

The Tenascin-C-Derived Peptide VSWRAPTA Promotes Neuronal Branching Via Transcellular Activation of the Focal Adhesion Kinase (FAK) and the ERK1/2 Signaling Pathway In Vitro

(2018) Marvin Jarocki et al.   MOLECULAR NEUROBIOLOGY

Identification of integrin drug targets for 17 solid tumor types

(2018) Adith S. Arun et al.   Oncotarget

A tension-mediated glycocalyx–integrin feedback loop promotes mesenchymal-like glioblastoma

(2018) J. Matthew Barnes et al.   NATURE CELL BIOLOGY

Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity

(2018) Reza Mirzaei et al.   OncoImmunology

Tenascin-C accelerates adverse ventricular remodelling after myocardial infarction by modulating macrophage polarization

(2018) Taizo Kimura et al.   CARDIOVASCULAR RESEARCH

Tenascin-C Produced by Intestinal Myofibroblasts Promotes Colitis-associated Cancer Development Through Angiogenesis

(2018) Takafumi Kawamura et al.   INFLAMMATORY BOWEL DISEASES

An RGD small-molecule integrin antagonist induces detachment-mediated anoikis in glioma cancer stem cells

(2018) Mayra Paolillo et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Extracellular matrix (ECM) stiffness and degradation as cancer drivers

(2018) Masoud Najafi et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma

(2018) Joni Leppänen et al.   PANCREAS

Tenascin C is a prognostic determinant and potential cancer-associated fibroblasts marker for breast ductal carcinoma

(2017) Zhaoting Yang et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

The Promoting Effect of the Extracellular Matrix Peptide TNIIIA2 Derived from Tenascin-C in Colon Cancer Cell Infiltration

(2017) Hideo Suzuki et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Emergence of Small-Molecule Non-RGD-Mimetic Inhibitors for RGD Integrins

(2017) Lisa M. Miller et al.   JOURNAL OF MEDICINAL CHEMISTRY

Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival

(2017) Vasilena Gocheva et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update

(2017) Laure Malric et al.   Oncotarget

Exploring the Role of RGD-Recognizing Integrins in Cancer

(2017) Markus Nieberler et al.   Cancers

Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment

(2016) Genichiro Ishii et al.   ADVANCED DRUG DELIVERY REVIEWS

Glioma cell dispersion is driven by α5 integrin-mediated cell–matrix and cell–cell interactions

(2016) Anne-Florence Blandin et al.   CANCER LETTERS

Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen

(2016) Heather M. Brechbuhl et al.   CLINICAL CANCER RESEARCH

Tenascin-C at a glance

(2016) Kim S. Midwood et al.   JOURNAL OF CELL SCIENCE

Tenascin-C, a Prognostic Determinant of Esophageal Squamous Cell Carcinoma

(2016) Zhao-Ting Yang et al.   PLoS One

Tenascin-C drives persistence of organ fibrosis

(2016) Swati Bhattacharyya et al.   Nature Communications

Tenascin-C Orchestrates Glioblastoma Angiogenesis by Modulation of Pro- and Anti-angiogenic Signaling

(2016) Tristan Rupp et al.   Cell Reports

Matricryptins Network with Matricellular Receptors at the Surface of Endothelial and Tumor Cells

(2016) Sylvie Ricard-Blum et al.   Frontiers in Pharmacology

Coadministration of the FNIII14 Peptide Synergistically Augments the Anti-Cancer Activity of Chemotherapeutic Drugs by Activating Pro-Apoptotic Bim

(2016) Takuya Iyoda et al.   PLoS One

Identification and Characterization of Novel Matrix-Derived Bioactive Peptides: A Role for Collagenase from Santyl® Ointment in Post-Debridement Wound Healing?

(2016) Anthony R. Sheets et al.   PLoS One

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)

(2015) J. Vansteenkiste et al.   ANNALS OF ONCOLOGY

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

(2015) L. Burt Nabors et al.   NEURO-ONCOLOGY

ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor–initiating cells

(2015) Susobhan Sarkar et al.   NEURO-ONCOLOGY

PDGF-B Can Sustain Self-renewal and Tumorigenicity of Experimental Glioma-Derived Cancer-Initiating Cells by Preventing Oligodendrocyte Differentiation

(2015) Yiwen Jiang et al.   NEOPLASIA

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

(2014) J. B. Vermorken et al.   ANNALS OF ONCOLOGY

PDGFR-β-activated ACK1-AKT Signaling Promotes Glioma Tumorigenesis

(2014) Jiannan Zhang et al.   INTERNATIONAL JOURNAL OF CANCER

Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells

(2014) YOSHIHIRO NAKAGAWA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Tenascin-C-derived Peptide TNIIIA2 Highly Enhances Cell Survival and Platelet-derived Growth Factor (PDGF)-dependent Cell Proliferation through Potentiated and Sustained Activation of Integrin α5β1

(2014) Rika Tanaka et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

(2014) Roger Stupp et al.   LANCET ONCOLOGY

Revisiting the matricellular concept

(2014) Joanne E. Murphy-Ullrich et al.   MATRIX BIOLOGY

Platelet-derived growth factor in glioblastoma—driver or biomarker?

(2014) Bengt Westermark   UPSALA JOURNAL OF MEDICAL SCIENCES

Tenascin-C: Form versus function

(2014) Sean P Giblin et al.   Cell Adhesion & Migration

Anoikis molecular pathways and its role in cancer progression

(2013) Paolo Paoli et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

 1 Integrin Targeting Potentiates Antiangiogenic Therapy and Inhibits the Growth of Bevacizumab-Resistant Glioblastoma

(2013) W. S. Carbonell et al.   CANCER RESEARCH

Matrix Stiffness Corresponding to Strictured Bowel Induces a Fibrogenic Response in Human Colonic Fibroblasts

(2013) Laura A. Johnson et al.   INFLAMMATORY BOWEL DISEASES

SLLISWD Sequence in the 10FNIII Domain Initiates Fibronectin Fibrillogenesis

(2013) Elaine P. S. Gee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Fibronectin Peptides that Bind PDGF-BB Enhance Survival of Cells and Tissue under Stress

(2013) Fubao Lin et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Laminin-111-derived peptides and cancer

(2013) Yamato Kikkawa et al.   Cell Adhesion & Migration

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)

(2012) L. Burt Nabors et al.   CANCER

Integrin  5 1 Plays a Critical Role in Resistance to Temozolomide by Interfering with the p53 Pathway in High-Grade Glioma

(2012) H. Janouskova et al.   CANCER RESEARCH

Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy

(2012) M. DeLay et al.   CLINICAL CANCER RESEARCH

Eukaryotic Translation Elongation Factor 1A Induces Anoikis by Triggering Cell Detachment

(2012) Keisuke Itagaki et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PDGF and PDGF receptors in glioma

(2012) Inga Nazarenko et al.   UPSALA JOURNAL OF MEDICAL SCIENCES

Reconstruction of integrin activation

(2011) F. Ye et al.   BLOOD

Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part

(2011) J B Vermorken et al.   BRITISH JOURNAL OF CANCER

HB-EGF and PDGF Mediate Reciprocal Interactions of Carcinoma Cells with Cancer-Associated Fibroblasts to Support Progression of Uterine Cervical Cancers

(2011) T. Murata et al.   CANCER RESEARCH

Advances in tenascin-C biology

(2011) Kim S. Midwood et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization

(2011) J. T. O'Connell et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

α5β1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells

(2010) Eva Martinkova et al.   INTERNATIONAL JOURNAL OF CANCER

Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium

(2010) Deborah A. Bradley et al.   INVESTIGATIONAL NEW DRUGS

Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium

(2010) Ajjai Alva et al.   INVESTIGATIONAL NEW DRUGS

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

(2010) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

Extracellular Matrix of Glioblastoma Inhibits Polarization and Transmigration of T Cells: The Role of Tenascin-C in Immune Suppression

(2010) J.-Y. Huang et al.   JOURNAL OF IMMUNOLOGY

The final steps of integrin activation: the end game

(2010) Sanford J. Shattil et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Endogenous tenascin-C enhances glioblastoma invasion with reactive change of surrounding brain tissue

(2009) Eishu Hirata et al.   CANCER SCIENCE

Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling

(2009) Kandice R. Levental et al.   CELL

VLA-5-mediated Adhesion to Fibronectin Accelerates Hemin-stimulated Erythroid Differentiation of K562 Cells through Induction of VLA-4 Expression

(2009) Rika Tanaka et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease

(2009) Kim Midwood et al.   NATURE MEDICINE

Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations

(2009) Cameron Brennan et al.   PLoS One

Peptide array-based screening of human mesenchymal stem cell-adhesive peptides derived from fibronectin type III domain

(2008) Mina Okochi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth

(2008) F. Donate et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY

Colorectal cancer and dysplasia in inflammatory bowel disease

(2008) Timothy L Zisman et al.   WORLD JOURNAL OF GASTROENTEROLOGY